$NASDAQ:SAGE

Deadline Approaching for Sage Therapeutics Investors to File Class Action Lawsuit, Law Firm Reminds
Gallery

Deadline Approaching for Sage Therapeutics Investors to File Class Action Lawsuit, Law Firm Reminds

🌧️Trending News Sage Therapeutics ($NASDAQ:SAGE) is a biopharmaceutical company that focuses on developing and commercializing novel medicines to treat neurological [...]

By GoodWhale|October 29, 2024|Categories: Biotechnology|Tags: $NASDAQ:SAGE, Biotechnology, NASDAQ|0 Comments

Sage Therapeutics Intrinsic Value – SAGE Therapeutics Investors Granted Chance to Pursue Securities Fraud Lawsuit with Schall Law Firm
Gallery

Sage Therapeutics Intrinsic Value – SAGE Therapeutics Investors Granted Chance to Pursue Securities Fraud Lawsuit with Schall Law Firm

🌧️Trending News SAGE ($NASDAQ:SAGE) Therapeutics is a biopharmaceutical company that focuses on the development of novel treatments for central nervous [...]

By GoodWhale|September 6, 2024|Categories: Biotechnology, Intrinsic Value|Tags: $NASDAQ:SAGE, Biotechnology, NASDAQ|0 Comments

Sage Therapeutics Shares Surge Above 50-Day Moving Average
Gallery

Sage Therapeutics Shares Surge Above 50-Day Moving Average

☀️Trending News Sage Therapeutics ($NASDAQ:SAGE) is a biopharmaceutical company that specializes in developing novel medicines to treat central nervous system [...]

By GoodWhale|December 30, 2023|Categories: Biotechnology|Tags: $NASDAQ:SAGE, Biotechnology, NASDAQ|0 Comments

Sage Therapeutics Stock Fair Value – Biogen and Sage Therapeutics Team up to Launch Depression Therapy in U.S.
Gallery

Sage Therapeutics Stock Fair Value – Biogen and Sage Therapeutics Team up to Launch Depression Therapy in U.S.

🌧️Trending News Biogen and Sage Therapeutics ($NASDAQ:SAGE) have announced the launch of a new treatment for depression in the United [...]

By GoodWhale|December 16, 2023|Categories: Biotechnology, Intrinsic Value|Tags: $NASDAQ:SAGE, Biotechnology, NASDAQ|0 Comments

Sage Therapeutics Stock Fair Value – SAGE THERAPEUTICS Reports Strong Q3 FY2023 Financial Results
Gallery

Sage Therapeutics Stock Fair Value – SAGE THERAPEUTICS Reports Strong Q3 FY2023 Financial Results

☀️Earnings Overview SAGE THERAPEUTICS ($NASDAQ:SAGE) reported total revenue of USD 2.7 million for Q3 FY2023 on September 30 2023, a [...]

By GoodWhale|November 23, 2023|Categories: Biotechnology, Earnings Report, Intrinsic Value|Tags: $NASDAQ:SAGE, Biotechnology, NASDAQ|0 Comments

Victory Capital Management Invests $1.98 Million in Sage Therapeutics
Gallery

Victory Capital Management Invests $1.98 Million in Sage Therapeutics

🌥️Trending News Victory Capital Management Inc. recently made a major investment in Sage Therapeutics ($NASDAQ:SAGE) Inc., with an injection of [...]

By GoodWhale|November 1, 2023|Categories: Biotechnology|Tags: $NASDAQ:SAGE, Biotechnology, NASDAQ|0 Comments

SAGE THERAPEUTICS Sees 64.7% Increase in Total Revenue to USD 2.5 Million for Q2 of FY2023
Gallery

SAGE THERAPEUTICS Sees 64.7% Increase in Total Revenue to USD 2.5 Million for Q2 of FY2023

☀️Earnings Overview At the close of SAGE THERAPEUTICS ($NASDAQ:SAGE)' second quarter of FY2023, total revenue had risen 64.7% to USD [...]

By GoodWhale|August 14, 2023|Categories: Biotechnology, Earnings Report, Profitability|Tags: $NASDAQ:SAGE, Biotechnology, NASDAQ|0 Comments

Sage Therapeutics Receives ‘Hold’ Recommendation from Brokerages
Gallery

Sage Therapeutics Receives ‘Hold’ Recommendation from Brokerages

🌥️Trending News Sage Therapeutics ($NASDAQ:SAGE), Inc., a leading pharmaceutical company, has recently received a “Hold” recommendation from brokerages at Defense [...]

By GoodWhale|July 15, 2023|Categories: Biotechnology|Tags: $NASDAQ:SAGE, Biotechnology, NASDAQ|0 Comments

Sage Therapeutics Closes Day with 8.86% Drop Despite Key Growth Catalyst
Gallery

Sage Therapeutics Closes Day with 8.86% Drop Despite Key Growth Catalyst

🌧️Trending News Sage Therapeutics ($NASDAQ:SAGE) Inc., a biopharmaceutical company focused on developing and commercializing novel medicines to treat life-altering central [...]